European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update
(2024) In European Urology 86(6). p.531-549- Abstract
Background and objective: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. Methods: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise... (More)
Background and objective: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. Methods: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key findings and limitations: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients’ risk stratification and treating them appropriately. Conclusions and clinical implications: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.
(Less)
- author
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bacillus Calmette-Guérin, Bacillus Calmette-Guérin unresponsive, Bladder cancer, Classification, Cystoscopy, Diagnosis, Follow-up, Guidelines, Intravesical chemotherapy, Prognosis, Radical cystectomy, Transurethral resection, Urothelial carcinoma
- in
- European Urology
- volume
- 86
- issue
- 6
- pages
- 531 - 549
- publisher
- Elsevier
- external identifiers
-
- pmid:39155194
- scopus:85201500018
- ISSN
- 0302-2838
- DOI
- 10.1016/j.eururo.2024.07.027
- language
- English
- LU publication?
- yes
- id
- 251474d1-2b10-401a-8319-a5bbc67cce17
- date added to LUP
- 2024-11-01 10:31:53
- date last changed
- 2025-07-12 22:13:21
@article{251474d1-2b10-401a-8319-a5bbc67cce17,
abstract = {{<p>Background and objective: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. Methods: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key findings and limitations: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients’ risk stratification and treating them appropriately. Conclusions and clinical implications: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.</p>}},
author = {{Gontero, Paolo and Birtle, Alison and Capoun, Otakar and Compérat, Eva and Dominguez-Escrig, José L. and Liedberg, Fredrik and Mariappan, Paramananthan and Masson-Lecomte, Alexandra and Mostafid, Hugh A. and Pradere, Benjamin and Rai, Bhavan P. and van Rhijn, Bas W.G. and Seisen, Thomas and Shariat, Shahrokh F. and Soria, Francesco and Soukup, Viktor and Wood, Robert and Xylinas, Evanguelos N.}},
issn = {{0302-2838}},
keywords = {{Bacillus Calmette-Guérin; Bacillus Calmette-Guérin unresponsive; Bladder cancer; Classification; Cystoscopy; Diagnosis; Follow-up; Guidelines; Intravesical chemotherapy; Prognosis; Radical cystectomy; Transurethral resection; Urothelial carcinoma}},
language = {{eng}},
number = {{6}},
pages = {{531--549}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update}},
url = {{http://dx.doi.org/10.1016/j.eururo.2024.07.027}},
doi = {{10.1016/j.eururo.2024.07.027}},
volume = {{86}},
year = {{2024}},
}